(Sharecast News) - 4basebio said on Wednesday that it had signed a clinical supply agreement with a cancer immunotherapy company to provide GMP-grade opDNA starting material for a Phase II clinical trial.
The AIM-listed synthetic DNA specialist said the multi-year agreement was expected to generate an approximate seven-figure revenue stream over...

Email this article to a friend

or share it with one of these popular networks:

• DIGG
• FACEBOOK
• STUMBLEUPON
• MIXX
• YAHOO BUZZ
• DELICIOUS
• REDDIT
• NEWSVINE